ZHANG Ya-ting, LI Pei, HE Yi-di, LI Yi-tong, LI Yu-min. The Relationship of 14-3-3ζ Protein Expression and Gastric Cancer: A Meta-AnalysisJ. Journal of Evidence-Based Medicine, 2020, 20(2): 89-95. DOI: 10.12019/j.issn.1671-5144.2020.02.007
Citation:
ZHANG Ya-ting, LI Pei, HE Yi-di, LI Yi-tong, LI Yu-min. The Relationship of 14-3-3ζ Protein Expression and Gastric Cancer: A Meta-AnalysisJ. Journal of Evidence-Based Medicine, 2020, 20(2): 89-95. DOI: 10.12019/j.issn.1671-5144.2020.02.007
ZHANG Ya-ting, LI Pei, HE Yi-di, LI Yi-tong, LI Yu-min. The Relationship of 14-3-3ζ Protein Expression and Gastric Cancer: A Meta-AnalysisJ. Journal of Evidence-Based Medicine, 2020, 20(2): 89-95. DOI: 10.12019/j.issn.1671-5144.2020.02.007
Citation:
ZHANG Ya-ting, LI Pei, HE Yi-di, LI Yi-tong, LI Yu-min. The Relationship of 14-3-3ζ Protein Expression and Gastric Cancer: A Meta-AnalysisJ. Journal of Evidence-Based Medicine, 2020, 20(2): 89-95. DOI: 10.12019/j.issn.1671-5144.2020.02.007
The Relationship of 14-3-3ζ Protein Expression and Gastric Cancer: A Meta-Analysis
No content published by the Journal of Evidence-Based Medicine may be reproduced or abridged without authorization. Please do not use or copy the layout and design of the journal without permission.
All articles published represent the opinions of the authors, and do not reflect the official policy of the Journal of Evidence-Based Medicine’ Sponsors or the Editorial Board, unless this is clearly specified.
Objective To evaluate the correlation between the expression web of Science of 14-3-3ζ protein and gastric cancer. Methods CNKI, VIP, CBM, WanFang Data, PubMed, Cochrane Library and EMBASE,were searched to identify studies on 14-3-3ζ expression for gastric cancer before November 14th,2019. Meta-analysis was performed using RevMan 5.3.5 software after screening the literature, extracting data, and evaluating the risk of bias in the included studies. Results A total of 671 cases of gastric cancer were included in the cross-sectional study. Among them, 14-3-3ζ protein was high expressed in 414 cases and low expressed in 257. Meta-analysis shows that 14-3-3ζ protein was high expressed in gastric cancer tissues (OR=4.94, 95%CI 1.29 to 18.82, P=0.02), and its high expression was more common in tumors with clinical stage Ⅲ~Ⅳ gastric cancer patients (OR=0.34, 95%CI 0.12 to 0.92, P=0.03); but with age (OR=0.87, 95% CI 0.59 to 1.28, P=0.48), gender (OR=1.11, 95%CI 0.72 to 1.69, P=0.64) as well as tumor size (0.74,95%CI 0.30 to 1.84, P=0.02)had no significant relationship. 1-year HR=18.25,95%CI(6.53,51.04),P<0.000 01,2-year(HR=24.37, 95%CI 9.25 to 64.25, P<0.000 01),3-year (HR=20.90, 95%CI 7.01 to 62.31, P<0.000 01) and 5-year overall survival rate(HR=19.03, 95%CI 7.02 to 51.62, P<0.000 01) of 14-3-3ζ protein low expression group were significantly higher than high expression group. Conclusion The expression of 14-3-3ζ protein is markedly correlated with clinical stage and the prognosis of gastric cancer.